Table 1

Clinical findings at study entry in patients with early rheumatoid arthritisa

Parameters

Data (N = 50)


Demographics

Age, years (range)

52 (30 to 80)

Sex, females/males

36/14

Smoking history, n (%)

Current

8 (16)

Former

9 (18)

Never

33 (66)

Disease duration, months

4 (1 to 12)

Autoantibodies

Rheumatoid factor (RF), no. positive (%)

30 (60)

Anti-CCP

39 (78)

RF or anti-CCP

42 (84)

Inflammatory indices

Erythrocyte sedimentation rate (ESR), mm/h (range)

23 (3 to 98)

C-reactive protein (CRP), mg/L (range)

7.6 (0.2 to 118)

Disease activity

DAS28-ESR

4.7 (1.6 to 8.1)

Tender joint count (TJC), n (range)

8 (0 to 26)

Swollen joint count (SJC), n (range)

3 (0 to 23)

Clinical Disease Activity Index (CDAI)

19.2 (2 to 57.7)

Health Assessment Questionnaire (HAQ)

0.35 (0 to 2.55)

Medications prior to study entry, n (%)

Prednisone

13 (26)

Nonsteroidal anti-inflammatory drug (NSAID)

30 (60)

Methotrexate (MTX)

0

Tumor necrosis factor (TNF) inhibitor

0


aData are expressed as median (interquartile range) values unless otherwise noted. Anti-cyclic citrullinated peptide: anti-CCP; DAS28: Disease Activity Score based on 28-joint count.

Arvikar et al. Arthritis Research & Therapy 2013 15:R109   doi:10.1186/ar4289

Open Data